Compare LMND & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LMND | ABCL |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.5B |
| IPO Year | 2020 | 2020 |
| Metric | LMND | ABCL |
|---|---|---|
| Price | $53.41 | $11.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $70.86 | $8.40 |
| AVG Volume (30 Days) | 875.2K | ★ 9.0M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.40 | 10.91 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $737,900,000.00 | $75,128,000.00 |
| Revenue This Year | $65.20 | N/A |
| Revenue Next Year | $33.31 | $21.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 40.15 | ★ 160.56 |
| 52 Week Low | $46.16 | $2.75 |
| 52 Week High | $99.90 | $12.58 |
| Indicator | LMND | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 52.19 | 62.32 |
| Support Level | $51.57 | $3.39 |
| Resistance Level | $56.71 | $12.58 |
| Average True Range (ATR) | 1.96 | 0.74 |
| MACD | 0.56 | -0.15 |
| Stochastic Oscillator | 78.36 | 51.17 |
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes. The company is using technology, data, artificial intelligence, contemporary design, and social impact to deliver delightful and affordable insurances. The Company operates in one report segment providing personal property and casualty insurance products within the United States and Europe, including the UK.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.